Cover Image

Donor T cells for CAR T cell therapy

Abstract Adoptive cell therapy using patient-derived chimeric receptor antigen (CAR) T cells redirected against tumor cells has shown remarkable success in treating hematologic cancers. However, wider accessibility of cellular therapies for all patients is needed. Manufacture of patient-derived CAR...

Full description

Saved in:

Bibliographic Details
Main Authors:	Tiffany C. Y. Tang (Author), Ning Xu (Author), Robert Nordon (Author), Michelle Haber (Author), Kenneth Micklethwaite (Author), Alla Dolnikov (Author)
Format:	Book
Published:	BMC, 2022-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Biomarkers as targets for CAR-T/NK cell therapy in AML
by: Ruonan Shao, et al.
Published: (2023)

Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy
by: Dian Xiong, et al.
Published: (2024)

Updates on CAR T cell therapy in multiple myeloma
by: Fatemeh Nasiri, et al.
Published: (2024)

Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy
by: Si-Heng Zhang, et al.
Published: (2024)

CAR-based cell therapy: evaluation with bibliometrics and patent analysis
by: Yajun Yuan, et al.
Published: (2021)

CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy
by: Behrouz Shademan, et al.
Published: (2022)

Identification of cancer-specific cell surface targets for CAR-T cell therapy
by: Naoki Hosen
Published: (2024)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
by: Laura Castelletti, et al.
Published: (2021)

CAR-T Cell Therapy: Advances in Kidney-Related Diseases
by: Longyuan Wu, et al.
Published: (2024)

Post-CAR-T cell therapy presenting as proteinaceous lymphadenopathy
by: Mishi Bhushan, et al.
Published: (2021)

Model‐informed drug development of autologous CAR‐T cell therapy: Strategies to optimize CAR‐T cell exposure leveraging cell kinetic/dynamic modeling
by: Anna M. Mc Laughlin, et al.
Published: (2023)

Engineering CAR-T cells
by: Cheng Zhang, et al.
Published: (2017)

Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma
by: Shuto Negishi, et al.
Published: (2024)

CAR T Cell Therapy: Remedies of Current Challenges in Design, Injection, Infiltration and Working
by: Zhu Y, et al.
Published: (2023)

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
by: Zijun Zhao, et al.
Published: (2018)

Immunogenicity in CAR T cell immunotherapy
by: Emily Yu
Published: (2023)

Effects of CAR-T Cell Therapy on Immune Cells and Related Toxic Side Effect Analysis in Patients with Refractory Acute Lymphoblastic Leukemia
by: Lianlian Li, et al.
Published: (2023)

Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
by: Tadesse Asmamaw Dejenie, et al.
Published: (2022)

Emerging CAR T cell therapies: clinical landscape and patent technological routes
by: Virgínia Picanco-Castro, et al.
Published: (2020)

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
by: Zhenguang Wang, et al.
Published: (2018)

Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin's Lymphoma
by: Maria Giraudo, et al.
Published: (2024)

Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects
by: Javad Masoumi, et al.
Published: (2021)

The EBMT/EHA CAR-T Cell Handbook
Published: (2022)

The EBMT/EHA CAR-T Cell Handbook
Published: (2022)

The EBMT/EHA CAR-T Cell Handbook
Published: (2022)

Seatbelts in CAR therapy: How Safe Are CARS?
by: Kentaro Minagawa, et al.
Published: (2015)

Lyophilized lymph nodes: A paradigm shift in CAR T-cell delivery for solid tumor therapy
by: Qiuhua Luo, et al.
Published: (2024)

CRISPR/Cas-based CAR-T cells: production and application
by: Ping Song, et al.
Published: (2024)

Single-cell analysis of the survival mechanisms of fratricidal CAR-T targeting of T cell malignancies
by: Hui Hu, et al.
Published: (2024)

The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions
by: Yanping Li, et al.
Published: (2022)

CAR-T Cell Therapies for Non-Hematopoietic Malignancies: Taking Off The Training Wheels
Published: (2020)

Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies
by: Hamed Dabiri, et al.
Published: (2023)

Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective
by: Xingxing Qi, et al.
Published: (2023)

Breaking through the treatment desert of conventional mesothelin-targeted CAR-T cell therapy for malignant mesothelioma: A glimpse into the future
by: Yuning Wang, et al.
Published: (2024)

Nanobody-based CAR-T cells for cancer immunotherapy
by: Pouya Safarzadeh Kozani, et al.
Published: (2022)

New cell sources for CAR-based immunotherapy
by: Marzieh Mazinani, et al.
Published: (2023)

Immunotherapy with CAR-T cells in paediatric haematology-oncology
by: Isabel Mirones, et al.
Published: (2020)

Correction: CRISPR/Cas-based CAR-T cells: production and application
by: Ping Song, et al.
Published: (2024)

CAR T-Cell Therapies in Italy: Patient Access Barriers and Recommendations for Health System Solutions
by: Claudio Jommi, et al.
Published: (2022)

The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
by: Forsberg MH, et al.
Published: (2018)